CBD and Depression: Exploring the Research

Depression is one of the most common mood disorders in clinical practice. Despite its prevalence, fewer than half of patients achieve full remission, and many do not respond to antidepressants and/or psychotherapy.¹ This has prompted interest in adjunctive options, including cannabis constituents such as cannabidiol (CBD).² Emerging evidence suggests CBD may enhance mood and relieve depressive symptoms, with early signals for potential roles in bipolar disorder, major depressive disorder (MDD), and treatment-resistant depression.

How Does the Endocannabinoid System (ECS) Influence Mood?

A healthy ECS supports cognition, motivation, emotion, sleep, and the stress response via endogenous cannabinoids acting at CB1 and CB2 receptors.³ CB1 receptors, primarily in the central and peripheral nervous systems, modulate norepinephrine, serotonin, dopamine, GABA, and glutamate systems;^3,4 CB2 receptors, largely on leukocytes, influence inflammation and immune regulation.³

Preclinically, CB1 deletion or antagonism produces depressive-like phenotypes, whereas CB1 agonism shows antidepressant effects.³ Human data also implicate CB1 dysfunction in depressive symptomatology;⁴ notably, rimonabant (a CB1 antagonist) caused depression and suicidality and was withdrawn.⁵ CB2 appears secondary but relevant: CB2 agonists reverse depressive behaviors in animals.^3,4

In MDD, some patients exhibit altered ECS receptor expression and genetic variants—especially in treatment-resistant cases.³ Women with MDD show reduced circulating 2-AG,⁶ while other studies find elevated endocannabinoids in depressed and suicide victims.⁴ Collectively, ECS alterations may contribute to mood disorders.

How CBD May Influence Mood

CBD, the second most abundant phytocannabinoid, crosses the blood–brain barrier and modulates cognition and emotion.⁷ It indirectly influences CB1/CB2 signaling and acts as a partial 5-HT1A agonist, enhancing serotonin binding;^3,8 it may also increase GABA, calming CNS activity.³

Preclinical/early clinical evidence suggests CBD favorably affects the HPA axis, neurogenesis, and neuroinflammation—processes implicated in depression.^3,9 Animal data indicate fast-acting antidepressant properties targeting brain structures linked to mood regulation.⁷ Given anxiety–depression comorbidity, accumulating evidence also supports CBD’s anxiolytic effects and stress modulation.^7,10,11

CBD and Depression: Clinical Studies

Surveys report many depressed patients self-medicate with cannabis/CBD,^2,7,12 though heavy cannabis use may increase depression risk (data are mixed).^5,13–15

In regular heavy cannabis users, daily 200 mg CBD reduced depressive and psychotic symptoms and blunted euphoria—consistent with CBD counteracting THC’s CB1-mediated psychoactivity.^16,17

In bipolar depression, a 12-week randomized, double-blind, placebo-controlled pilot (150–300 mg/day; n=35) found significant MADRS reductions overall but no difference versus placebo, underscoring the need for larger/higher-dose trials.¹⁸ Ongoing studies are evaluating higher-dose CBD in treatment-resistant bipolar depression.^19,20

What About Dosing?

Self-medication surveys suggest most users take <50 mg/day; only ~17% exceed 100 mg/day.⁷ Clinical work supports tolerability up to 6000 mg, with common adverse effects including GI upset, somnolence, and decreased appetite; CBD is non-addictive.⁷

Drug interactions: CBD inhibits CYP3A4 and CYP2D6, potentially raising serum levels of many antidepressants/psychiatric medications; monitor closely if co-administered.²¹

CBD and Mood Support: A Safer Consideration

Preclinical and early clinical findings suggest CBD may modulate mood regulation, neuroinflammation, and stress pathways. Larger, rigorous trials are needed to define efficacy, dosing, and long-term safety. Given persistent gaps in treating depression—especially treatment-resistant cases—CBD may be considered as an adjunct under clinical supervision.

References

1. Han MH, Nestler EJ. Neural Substrates of Depression and Resilience. Neurotherapeutics. 2017;14(3):677-686.
2. Wieckiewicz G et al. CBD in the Self-Treatment of Depression. Front Psychiatry. 2022;13:837946.
3. Zarazúa-Guzmán S et al. ECS as a Potential Target for Therapy. Basic Clin Pharmacol Toxicol. 2024;135(6):669-684.
4. Smaga I et al. Endocannabinoid/Endovanilloid System and Depression. Curr Neuropharmacol. 2014;12(5):462-474.
5. Bright U, Akirav I. ECS Components in Depression. Int J Mol Sci. 2022;23(10).
6. Hill MN et al. Serum Endocannabinoids in Female MDD. Pharmacopsychiatry. 2008;41(2):48-53.
7. Binkowska AA et al. CBD Usage, Efficacy, and Side Effects. Front Psychiatry. 2024;15:1356009.
8. Russo EB et al. CBD at 5-HT1A Receptors. Neurochem Res. 2005;30(8):1037-1043.
9. Gallego-Landin I et al. ECS in Depression Pathophysiology. Front Pharmacol. 2021;12:762738.
10. Kalin NH. Anxiety–Depression Relationship. Am J Psychiatry. 2020;177(5):365-367.
11. Crippa JA et al. Therapeutic Potential of CBD. Front Immunol. 2018;9:2009.
12. Li X et al. Cannabis Flower and Depression Relief. Yale J Biol Med. 2020;93(2):251-264.
13. Feingold D, Weinstein A. Cannabis and Depression. Adv Exp Med Biol. 2021;1264:67-80.
14. Jefsen OH et al. CUD and Risk of Mood Disorders. JAMA Psychiatry. 2023;80(8):803-810.
15. Churchill V et al. Cannabis–Depression Meta-analysis. Psychol Med. 2025;55:e44.
16. Beale C et al. CBD and Hippocampal Subfields in Users. Cannabis Cannabinoid Res. 2018;3(1):94-107.
17. Solowij N et al. Prolonged CBD in Regular Users. Cannabis Cannabinoid Res. 2018;3(1):21-34.
18. Pinto JV et al. CBD Adjunct in Acute Bipolar Depression: Pilot. Can J Psychiatry. 2024;69(4):242-251.
19. Walji N. CBD Adjunctive Therapy in Bipolar Depression. ClinicalTrials.gov: NCT05867849 (2025).
20. Smith R. CBD for Anxiety/Depression in Bipolar Disorder. ClinicalTrials.gov: NCT05457465 (2025).
21. Skelley JW et al. CBD in Anxiety and Related Disorders. J Am Pharm Assoc. 2020;60(1):253-261.